CME Group Inc. $CME Shares Purchased by Fayez Sarofim & Co

Posted by Micah Haroldson on Mar 16th, 2026

Fayez Sarofim & Co increased its stake in shares of CME Group Inc. (NASDAQ:CME – Free Report) by 0.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,249,296 shares of the financial services provider’s stock after buying an additional 7,866 shares during the quarter. Fayez Sarofim & Co owned about 0.35% of CME Group worth $337,547,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caldwell Trust Co raised its holdings in shares of CME Group by 116.3% during the 3rd quarter. Caldwell Trust Co now owns 93 shares of the financial services provider’s stock worth $25,000 after acquiring an additional 50 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of CME Group in the third quarter valued at about $27,000. Financial Consulate Inc. acquired a new stake in CME Group during the third quarter worth about $28,000. Sagard Holdings Management Inc. purchased a new position in CME Group during the second quarter worth about $30,000. Finally, Corundum Trust Company INC acquired a new position in CME Group in the 3rd quarter valued at about $30,000. Institutional investors and hedge funds own 87.75% of the company’s stock.

CME Group News Summary

Here are the key news stories impacting CME Group this week:

Positive Sentiment: Rothschild & Co Redburn raised its price target on CME to $347 (maintaining a “neutral” rating), implying roughly double-digit upside from recent levels and offering fresh analyst support for the shares. Rothschild Co Redburn adjusts price target on CME to 347 from 333, maintains neutral rating
Neutral Sentiment: CME’s CEO Terry Duffy publicly warned that U.S. government intervention in oil futures markets would be highly damaging; exchanges including CME have voiced opposition to potential Treasury action. This raises policy/regulatory risk for energy derivatives but also underscores the exchange’s central role in market integrity — a factor that can support trading volumes in energy products if volatility rises. US intervention in oil futures would be ‘biblical disaster’, CME warns CME Group CEO warns against US intervention in oil futures markets US intervention in oil futures market could be disastrous: CME Group
Neutral Sentiment: Short-interest reporting in recent feeds shows zero or nonsensical values and appears to be a data anomaly rather than a real bearish signal; treat those short-interest items with caution. (Market impact minimal until corrected.)
Negative Sentiment: Insider selling: Ken Vroman (Chief Transformation Officer) sold about 5,160 shares (~$1.59M) and SEC filings show multiple recent insider sales across senior staff. While insider sales can be routine, the cadence and size may raise governance/owner-sentiment questions for some investors. CME Group’s Vroman sells $1.59 million in stock Insider Sale: Chief Transformation Officer of $CME Sells 5,160 Shares

CME Group Price Performance

CME Group stock opened at $311.40 on Monday. The company’s 50 day simple moving average is $295.80 and its 200-day simple moving average is $279.06. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.03 and a current ratio of 1.03. CME Group Inc. has a 1 year low of $248.53 and a 1 year high of $329.16. The company has a market capitalization of $112.29 billion, a price-to-earnings ratio of 27.90, a price-to-earnings-growth ratio of 3.36 and a beta of 0.24.

CME Group (NASDAQ:CME – Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.75 by $0.02. CME Group had a net margin of 62.45% and a return on equity of 14.65%. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the prior year, the company earned $2.52 earnings per share. The business’s quarterly revenue was up 8.1% on a year-over-year basis. As a group, equities research analysts expect that CME Group Inc. will post 10.49 earnings per share for the current year.

CME Group Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.30 per share. This is a boost from CME Group’s previous quarterly dividend of $1.25. The ex-dividend date is Tuesday, March 10th. This represents a $5.20 dividend on an annualized basis and a yield of 1.7%. CME Group’s dividend payout ratio (DPR) is currently 46.59%.

Insider Buying and Selling at CME Group

In other CME Group news, Director William R. Shepard bought 251 shares of CME Group stock in a transaction on Tuesday, December 30th. The shares were bought at an average cost of $278.37 per share, for a total transaction of $69,870.87. Following the acquisition, the director directly owned 258,710 shares in the company, valued at $72,017,102.70. This represents a 0.10% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bryan T. Durkin sold 4,200 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $309.65, for a total transaction of $1,300,530.00. Following the completion of the transaction, the director owned 43,007 shares of the company’s stock, valued at approximately $13,317,117.55. This trade represents a 8.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,248 shares of company stock valued at $1,616,700 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CME shares. Weiss Ratings upgraded shares of CME Group from a “buy (b+)” rating to a “buy (a-)” rating in a report on Monday, March 2nd. Raymond James Financial decreased their price objective on CME Group from $311.00 to $310.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. The Goldman Sachs Group increased their price objective on CME Group from $264.00 to $266.00 and gave the stock a “sell” rating in a research report on Monday, February 9th. TD Cowen raised their target price on CME Group from $305.00 to $328.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Finally, Erste Group Bank upgraded CME Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, CME Group has a consensus rating of “Hold” and a consensus target price of $303.53.

View Our Latest Report on CME

CME Group Profile

(Free Report)

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.